CD8A and congenital rubella syndrome: In summary, in this dose-finding study, 18 mg was the maximum tolerated dose of otelixizumab and 9 mg was identified as the dose with the better therapeutic index, given the low incidence of transient symptoms related to CRS, the lack of clinical EBV reactivation and early changes in immunophenotyping such as expansion of exhausted memory CD8+ T cells, which was more pronounced in participants defined as metabolic responders.